Mitochondrial Transcription Factor A and Mitochondrial Genome as Molecular Targets for Cisplatin-Based Cancer Chemotherapy

被引:24
|
作者
Kohno, Kimitoshi [1 ]
Wang, Ke-Yong [2 ]
Takahashi, Mayu [3 ]
Kurita, Tomoko [4 ]
Yoshida, Yoichiro [5 ]
Hirakawa, Masakazu [6 ]
Harada, Yoshikazu [7 ]
Kuma, Akihiro [8 ]
Izumi, Hiroto [9 ]
Matsumoto, Shinji [1 ]
机构
[1] Asahi Matsumoto Hosp, Kokuramimami Ku, Kitakyushu, Fukuoka 8000242, Japan
[2] Univ Occupat & Environm Hlth, Sch Med, Shared Use Res Ctr, Yahatanishi Ku, Kitakyushu, Fukuoka 8078555, Japan
[3] Univ Occupat & Environm Hlth, Sch Med, Dept Neurosurg, Yahatanishi Ku, Kitakyushu, Fukuoka 8078555, Japan
[4] Univ Occupat & Environm Hlth, Sch Med, Dept Gynecol, Yahatanishi Ku, Kitakyushu, Fukuoka 8078555, Japan
[5] Fukuoka Univ, Sch Med, Dept Surg Gastroenterol, Fukuoka 8140180, Japan
[6] Kyushu Univ, Beppu Hosp, Dept Radiol, Beppu, Oita 8740838, Japan
[7] Univ Occupat & Environm Hlth, Sch Med, Dept Pathol & Cell Biol, Yahatanishi Ku, Kitakyushu, Fukuoka 8078555, Japan
[8] Univ Occupat & Environm Hlth, Sch Med, Dept Internal Med 2, Yahatanishi Ku, Kitakyushu, Fukuoka 8078555, Japan
[9] Univ Occupat & Environm Hlth, Inst Ind Ecol Sci, Dept Occupat Pneumol, Yahatanishi Ku, Kitakyushu, Fukuoka 8078555, Japan
来源
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES | 2015年 / 16卷 / 08期
关键词
mtTFA; mtDNA; cisplatin; cancer chemotherapy; prognosis; BOX-BINDING-PROTEIN; DISEASE-SPECIFIC SURVIVAL; DRUG-RESISTANCE; GENE-EXPRESSION; CELL LINES; STEM-CELLS; COLORECTAL-CANCER; ANTICANCER DRUGS; DAMAGED DNA; APOPTOSIS;
D O I
10.3390/ijms160819836
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Mitochondria are important cellular organelles that function as control centers of the energy supply for highly proliferative cancer cells and regulate apoptosis after cancer chemotherapy. Cisplatin is one of the most important chemotherapeutic agents and a key drug in therapeutic regimens for a broad range of solid tumors. Cisplatin may directly interact with mitochondria, which can induce apoptosis. The direct interactions between cisplatin and mitochondria may account for our understanding of the clinical activity of cisplatin and development of resistance. However, the basis for the roles of mitochondria under treatment with chemotherapy is poorly understood. In this review, we present novel aspects regarding the unique characteristics of the mitochondrial genome in relation to the use of platinum-based chemotherapy and describe our recent work demonstrating the importance of the mitochondrial transcription factor A (mtTFA) expression in cancer cells.
引用
收藏
页码:19836 / 19850
页数:15
相关论文
共 50 条
  • [21] Choriocarcinoma of the gallbladderTreated with cisplatin-based chemotherapy
    Jen C. Wang
    Santos Angeles
    Peter Chak
    Ann B. Platt
    Nagabhushana Nimmagadda
    Medical Oncology, 2001, 18 : 165 - 169
  • [22] Reconciling differences in impact of molecular subtyping on response to cisplatin-based chemotherapy
    Mathieu Roumiguie
    Alberto Contreras-Sanz
    Gunjan Kumar
    Peter C. Black
    Nature Communications, 12
  • [23] Reconciling differences in impact of molecular subtyping on response to cisplatin-based chemotherapy
    Roumiguie, Mathieu
    Contreras-Sanz, Alberto
    Kumar, Gunjan
    Black, Peter C.
    NATURE COMMUNICATIONS, 2021, 12 (01)
  • [24] Mitochondrial transcription factor A contributes to cisplatin resistance in patients with estrogen receptor-positive breast cancer
    Gao, Wei
    Wu, Mei-Hong
    Wang, Ning
    Ying, Ming-Zheng
    Zhang, Ying-Yi
    Hua, Jing
    Chuan, Liu
    Wang, Ya-Jie
    MOLECULAR MEDICINE REPORTS, 2016, 14 (06) : 5304 - 5310
  • [25] Intraperitoneal cisplatin-based chemotherapy versus intravenous cisplatin-based chemotherapy for stage III ovarian cancer with minimal residual disease: 10 years experience
    Yeng, MS
    Juang, CM
    Twu, NF
    Chao, KC
    7TH BIENNIAL MEETING OF THE INTERNATIONAL GYNECOLOGIC CANCER SOCIETY, 1999, : 331 - 335
  • [26] Acetylation and phosphorylation of mitochondrial transcription factor a promote mitochondrial transcription processivity
    Reardon, Sean D.
    Mishanina, Tatiana V.
    BIOPHYSICAL JOURNAL, 2023, 122 (03) : 492A - 492A
  • [27] Cisplatin-Based Chemotherapy Is a Strong Risk Factor for Thromboembolic Events in Small-Cell Lung Cancer
    Lee, Yun-Gyoo
    Lee, Eunyoung
    Kim, Inho
    Lee, Keun-Wook
    Kim, Tae Min
    Lee, Se-Hoon
    Kim, Dong-Wan
    Heo, Dae Seog
    CANCER RESEARCH AND TREATMENT, 2015, 47 (04): : 670 - 675
  • [28] RETINAL TOXICITY AFTER CISPLATIN-BASED CHEMOTHERAPY IN PATIENTS WITH TESTICULAR CANCER
    Gild, Philipp
    Vetterlein, Malte W.
    Dieckmann, Klaus-Peter
    Matthies, Cord
    Wagner, Walter
    Ludwig, Tim A.
    Meyer, Christian P.
    Soave, Armin
    Dulz, Simon
    Asselborn, Niels H.
    Oechsle, Karin
    Bokemeyer, Carsten
    Becker, Andreas
    Fisch, Margit
    Hartmann, Michael
    Chun, Felix K. H.
    Kluth, Luis A.
    JOURNAL OF UROLOGY, 2017, 197 (04): : E1085 - E1085
  • [29] Treatment of Patients With Metastatic Urothelial Cancer "Unfit" for Cisplatin-Based Chemotherapy
    Galsky, Matthew D.
    Hahn, Noah M.
    Rosenberg, Jonathan
    Sonpavde, Guru
    Hutson, Thomas
    Oh, William K.
    Dreicer, Robert
    Vogelzang, Nicholas
    Sternberg, Cora N.
    Bajorin, Dean F.
    Bellmunt, Joaquim
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (17) : 2432 - 2438
  • [30] Survival of patients with advanced urothelial cancer treated with cisplatin-based chemotherapy
    Fossa, SD
    Sternberg, C
    Scher, HI
    Theodore, CH
    Mead, B
    Dearnaley, D
    Roberts, JT
    Skovlund, E
    BRITISH JOURNAL OF CANCER, 1996, 74 (10) : 1655 - 1659